James W. Green - May 21, 2021 Form 4 Insider Report for HARVARD BIOSCIENCE INC (HBIO)

Role
Chief Executive Officer, Director
Signature
/s/ David Sirois, by power of attorney
Stock symbol
HBIO
Transactions as of
May 21, 2021
Transactions value $
-$109,647
Form type
4
Date filed
5/25/2021, 04:26 PM
Previous filing
May 21, 2021
Next filing
Jun 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HBIO Common Stock Options Exercise $63.9K +24.3K +1.07% $2.63 2.3M May 21, 2021 Direct F1
transaction HBIO Common Stock Sale -$174K -24.3K -1.06% $7.14 2.28M May 21, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HBIO Stock option (right to buy) Options Exercise $0 -24.3K -6.45% $0.00 353K May 21, 2021 Common Stock 24.3K $2.63 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (a) an award of 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (c) 243,072 restricted stock units that will fully vest on July 8, 2021, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 823,176 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 670,358 shares of common stock beneficially owned by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $7.04 to $7.20, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Includes (a) the shares and awards described in footnote (1) above, less (b) the disposition of shares reported in footnote (2) above.
F4 The options vest in four equal installments on December 31, 2020, 2021, 2022 and 2023.